announc pipelin clinic readout on-track
messag mru report result increment pipelin updat mostli
in-lin expect compani announc new proprietari triclon
platform capabl gener antibodi target site reiterate guidanc
toward clinic updat across three bispecif antibodi program
repres next set key potenti catalyst view updat estim
reflect result maintain buy pt
mru expand capabl new proprietari triclon platform similar
biclon platform rapidli gener screen bispecif antibodi lead
identif compani newli announc triclon platform util common light
chain promot natur pair antibodi heavi chain gener multi-specif
antibodi potenti three distinct target epitop
broader pipelin track multipl bispecif clinic updat
per prior guidanc mru expect provid updat follow
 three cohort breast cancer well
data acut myeloid leukemia addit guidanc upon announc maximum
toler dose egfr dose escal data basket solid
tumor partner link continu enrol part
broader collabor develop potenti commerci bispecif
link look first clinic data jnj
egfr-cmet bispecif antibodi egfr-driven advanc non-smal cell lung cancer
nsclc may read-through posit mruss bispecif egfr
updat result reflect result maintain buy pt mru end
quarter cash invest compani expect provid
runway
page analyst certif import disclosur
valuat risk
arriv price target mru use discount cash flow analysi
use wacc consist clinical-stag
biotech compani cover proof-of-concept data well termin
growth rate risk includ regulatori commerci setback potenti
emerg new competitor lower product sale expect
page analyst certif import disclosur
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
